Traws Pharma, Inc. reported its financial results for the second quarter ended June 30, 2025, on August 14, 2025. The company's cash, cash equivalents, and short-term investments were approximately $13.1 million as of June 30, 2025, compared to $21.3 million as of December 31, 2024.
Revenue for Q2 2025 was $2.7 million, a substantial increase from $57 thousand in Q2 2024. This increase was primarily due to the recognition of $2.7 million in deferred revenue from the mutual termination of a legacy oncology licensing agreement in April 2025. The net loss for Q2 2025 significantly improved to $0.9 million, or $0.11 per basic and diluted common share, compared to a net loss of $123.1 million in Q2 2024, which included a one-time charge of $117.5 million for acquired in-process R&D.
Research and development expenses decreased to $2.3 million in Q2 2025 from $4.0 million in Q2 2024, mainly due to reduced oncology program and personnel expenses, partially offset by increased virology program costs. General and administrative expenses also decreased to $1.7 million from $2.0 million. The company reprioritized its clinical trial plans, focusing on ratutrelvir Phase 2 studies for COVID-19 and emphasizing stockpiling readiness for tivoxavir marboxil.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.